Lisata Therapeutics Inc
LSTABuild a strategy around LSTA
Lisata Therapeutics Inc AI Insights
Informational only. Not investment advice.Snapshot
- Cash burn of 17.3M TTM vs 19M cash on hand = ~13 months runway without dilution or new financing[Free Cash Flow TTM]
- P/S ratio 36.6x vs industry median 4.0x on just 1.1M TTM revenue - priced entirely on pipeline optionality[P/S Ratio]
- Zero debt with 17M working capital - clean balance sheet but R&D of 9.8M TTM consuming 46% of opex[Total Debt]
Watch Triggers
- Cash and Equivalents: Falls below 10M — Sub-6 month runway triggers emergency financing at distressed terms
- Issuance of Capital Stock: Exceeds 5M in any quarter — Signals dilutive raise - current holders face 15%+ ownership reduction
- Research and Development TTM: Drops below 8M — R&D cuts signal pipeline deprioritization or cash conservation mode
Bull Case
Debt-free balance sheet with 19M cash provides runway for clinical milestones without immediate dilution pressure. EV of just 20M means market assigns minimal value to pipeline.
R&D intensity (9.8M of 21M opex) signals active pipeline development. Any positive clinical data could re-rate stock given 36x P/S already prices in optionality.
Bear Case
13-month cash runway at current burn forces dilutive financing by early 2027. With 1.1M revenue TTM, no commercial engine exists to self-fund operations.
ROE of -71% and ROIC of -71% TTM reflect pre-commercial biotech reality. P/B of 2.3x means paying premium over liquidation value for unproven assets.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage LSTA's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary catalyst ahead: clinical data readout will either validate premium valuation or trigger 50%+ correction
- R&D spend 9.8M TTM focused on pipeline advancement
- Market cap 39M implies significant success probability
- Cash runway forces near-term financing decision
Valuation Context
Caveats
Public Strategies Rankings
See how Lisata Therapeutics Inc ranks across different investment strategies.
Leverage LSTA's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
LSTA Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$44.09M | — | ||
$28.14M | — | ||
0.00 | — | ||
$170,000 | -83.0% | — | |
$-1.91 | — | ||
-10,711% | -8470.3% | — | |
-9,756% | -7758.0% | — | |
$-15.98M | — | ||
-74.7% | -23.2% | — | |
Beta 5Y (Monthly) | unknown | — |
LSTA Dividend History
LSTA Stock Splits
LSTA SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
03/12/26 | 12/31/25 | 10-K | |
11/06/25 | 09/30/25 | 10-Q | |
08/07/25 | 06/30/25 | 10-Q | |
05/08/25 | 03/31/25 | 10-Q | |
02/27/25 | 12/31/24 | Unknown | |
11/12/24 | 09/30/24 | 10-Q | |
08/12/24 | 06/30/24 | 10-Q | |
05/09/24 | 03/31/24 | 10-Q | |
02/29/24 | 12/31/23 | 10-K | |
11/02/23 | 09/30/23 | 10-Q | |
08/14/23 | 06/30/23 | 10-Q | |
05/09/23 | 03/31/23 | 10-Q | |
03/30/23 | 12/31/22 | 10-K | |
11/10/22 | 09/30/22 | 10-Q | |
08/04/22 | 06/30/22 | 10-Q | |
05/05/22 | 03/31/22 | 10-Q | |
03/22/22 | 12/31/21 | 10-K | |
11/04/21 | 09/30/21 | 10-Q | |
08/05/21 | 06/30/21 | 10-Q | |
05/06/21 | 03/31/21 | 10-Q | |
02/25/21 | 12/31/20 | 10-K | |
11/05/20 | 09/30/20 | 10-Q | |
08/13/20 | 06/30/20 | 10-Q | |
05/07/20 | 03/31/20 | 10-Q | |
03/05/20 | 12/31/19 | 10-K | |
11/06/19 | 09/30/19 | 10-Q | |
08/08/19 | 06/30/19 | 10-Q | |
05/09/19 | 03/31/19 | 10-Q | |
03/14/19 | 12/31/18 | 10-K | |
11/08/18 | 09/30/18 | 10-Q | |
08/09/18 | 06/30/18 | 10-Q | |
05/10/18 | 03/31/18 | 10-Q | |
03/22/18 | 12/31/17 | 10-K | |
11/09/17 | 09/30/17 | 10-Q | |
08/10/17 | 06/30/17 | 10-Q | |
05/15/17 | 03/31/17 | 10-Q | |
03/17/17 | 12/31/16 | 10-K | |
11/07/16 | 09/30/16 | 10-Q | |
08/09/16 | 06/30/16 | 10-Q | |
05/05/16 | 03/31/16 | 10-Q | |
03/15/16 | 12/31/15 | 10-K | |
11/05/15 | 09/30/15 | 10-Q | |
08/06/15 | 06/30/15 | 10-Q | |
05/06/15 | 03/31/15 | 10-Q | |
03/02/15 | 12/31/14 | 10-K | |
10/30/14 | 09/30/14 | 10-Q | |
08/07/14 | 06/30/14 | 10-Q | |
05/08/14 | 03/31/14 | 10-Q | |
03/13/14 | 12/31/13 | 10-K | |
11/07/13 | 09/30/13 | 10-Q | |
08/08/13 | 06/30/13 | 10-Q | |
05/09/13 | 03/31/13 | 10-Q | |
03/11/13 | 12/31/12 | 10-K | |
11/13/12 | 09/30/12 | 10-Q | |
08/14/12 | 06/30/12 | 10-Q | |
05/11/12 | 03/31/12 | 10-Q | |
03/20/12 | 12/31/11 | 10-K | |
11/10/11 | 09/30/11 | 10-Q | |
08/12/11 | 06/30/11 | 10-Q | |
05/17/11 | 03/31/11 | 10-Q | |
04/06/11 | 12/31/10 | 10-K | |
11/12/10 | 09/30/10 | 10-Q | |
08/16/10 | 06/30/10 | 10-Q | |
05/17/10 | 03/31/10 | 10-Q | |
03/31/10 | 12/31/09 | 10-K | |
11/06/09 | 09/30/09 | 10-Q | |
08/13/09 | 06/30/09 | 10-Q | |
05/15/09 | 03/30/09 | 10-Q | |
03/31/09 | 12/31/08 | 10-K | |
11/14/08 | 09/30/08 | 10-Q | |
08/14/08 | 06/30/08 | 10-Q | |
05/15/08 | 03/30/08 | Unknown | -- |
03/28/08 | 12/31/07 | 10-K | |
09/30/07 | 09/30/07 | 10QSB | |
06/30/07 | 06/30/07 | 10QSB | |
03/31/07 | 03/30/07 | Unknown | -- |
03/29/07 | 12/31/06 | 10-K | |
11/14/06 | 09/30/06 | 10-Q | |
08/14/06 | 06/30/06 | 10-Q | |
05/22/06 | 03/30/06 | Unknown | -- |
04/03/06 | 12/31/05 | 8-K | |
11/14/05 | 09/30/05 | 10-Q | |
08/15/05 | 06/30/05 | 10-Q | |
05/16/05 | 03/30/05 | Unknown | -- |
03/31/05 | 12/31/04 | 10-K | |
11/12/04 | 09/30/04 | 10-Q | |
08/13/04 | 06/30/04 | 10-Q | |
05/11/04 | 03/30/04 | Unknown | -- |
03/30/04 | 12/31/03 | 10-K | |
09/30/03 | 09/30/03 | Unknown | -- |
08/14/03 | 06/30/03 | 10-Q | |
05/15/03 | 03/30/03 | Unknown | -- |
03/26/03 | 12/31/02 | 10-K | |
11/19/02 | 09/30/02 | NT 10-Q | |
09/06/02 | 06/30/02 | NT 10-Q | |
05/20/02 | 03/30/02 | Unknown | -- |
04/15/02 | 12/31/01 | NT 10-K | |
11/13/01 | 09/30/01 | 10-Q | |
08/20/01 | 06/30/01 | NT 10-Q | |
05/14/01 | 03/30/01 | Unknown | -- |
04/12/01 | 12/31/00 | NT 10-K | |
11/13/00 | 09/30/00 | 10-Q | |
08/15/00 | 06/30/00 | 10-Q | |
05/22/00 | 03/30/00 | Unknown | -- |